Mayo Clinic Laboratory and pathology research roundup: April 26

By Meghann Southwick • April 26, 2022

Share this:

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

Arrhythmia Variant Associations and Reclassifications in the eMERGE-III Sequencing Study.

Sequencing Mendelian arrhythmia genes in individuals without an indication for arrhythmia genetic testing can identify carriers of pathogenic or likely pathogenic (P/LP) variants. However, the extent to which these variants are associated with clinically meaningful phenotypes before or after return of variant results is unclear. In addition, the majority of discovered variants are currently classified as variants of uncertain significance, limiting clinical actionability.

Read more.

Published to PubMed This Week

• Association of latitude and altitude with adverse outcomes in patients with COVID-19: The VIRUS registry.
  World journal of critical care medicine
• The Effect of Diabetes-Associated Variation in TCF7L2 on Postprandial Glucose Metabolism When Glucagon and Insulin Concentrations Are Matched.
  Metabolic syndrome and related disorders
• Simulation and Artificial Intelligence in Rhinoplasty: A Systematic Review.
  Aesthetic plastic surgery
• KLF11 deficiency enhances chemokine generation and fibrosis in murine unilateral ureteral obstruction.
  PloS one
• Development of a PTHrP chemiluminescent immunoassay to assess humoral hypercalcemia of malignancy
  Clinical biochemistry
• Molecular characterization of Novel ATM fusions in chronic lymphocytic leukemia and T-cell prolymphocytic leukemia..
  Leukemia and lymphoma
• A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
  Cancer chemotherapy and pharmacology
• Human meniscus allograft augmentation by allogeneic mesenchymal stromal/stem cell injections.
  Journal of orthopaedic research
• Aberrant Expression of Lymphoid Enhancer-Binding Factor 1 (LEF1) in Hodgkin Lymphoma.
  Human pathology
• New Developments in the Understanding and Treatment of Autoimmune Hemolytic Anemia: Traditional and Novel Tests.
  Hematology/oncology clinics of North America

Meghann Southwick

Meghann Southwick is a marketing specialist for Mayo Clinic Laboratories. She has worked at Mayo Clinic since 2021.